About us

Novo Nordisk Pharmatech A/S is a pharmaceutical company and was established in 1949 as FeF Chemicals. In 1986 FeF Chemicals was acquired by Novo Nordisk, a world leader in diabetes care and a Danish healthcare company. Novo Nordisk Pharmatech has since then been part of the Novo Nordisk pharmaceutical group.

Novo Nordisk Pharmatech A/S is the leading worldwide supplier of products as recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the biopharmaceutical and pharmaceutical industries. We improve biopharmaceutical manufacturing by developing and supplying innovative products used in the manufacturing of biopharmaceuticals.

We as a company has attracted the leading pharmaceutical companies through our high product quality, extensive manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy.

Securing your end-to-end supply chain

Our history

About us 3


Facts & figures

Novo Nordisk Pharmatech Annual Report 2023

Our mission & vision


Enabling better medicines. Enabling better lives.


We are committed to providing sustainable pharmaceutical materials through innovative and customised solutions

Novo Nordisk - Pharmatech - Benzalkonium chloride

We are global

Company 3

Novo Nordisk Pharmatech is currently present in the following:

  • Headquarter & manufacturing exclusively in Denmark
  • Affiliate in Boston, USA
  • Branch office in Singapore
  • Distribution center in Indianapolis, USA


Corporate movie

Get a short introduction to Novo Nordisk Pharmatech.

The Novo Nordisk Way

About us 1
The Novo Nordisk Way describes the values and behaviours that guide everything we do. It is rooted in the principles and vision of our founders who set out on an ambitious journey to change diabetes in 1923.
Today, we are thousands of colleagues applying the same passion, skills and commitment to our purpose of driving change to defeat serious chronic diseases, built upon our heritage in diabetes.
These diseases affect hundreds of millions of people and are among the most urgent health challenges in the world. They can lead to life-threatening complications, placing a growing burden upon individuals, families and society. To fulfil our purpose, we apply our core capabilities to pioneer the discovery and development of innovative medicines. By making these accessible to patients throughout the world, we aim to lead in all the therapy areas in which we are present, with the ultimate aspiration to prevent and cure disease.
Our ambition is to be a sustainable business respected for adding value to society. When faced with difficult choices, we think long-term, understanding that our future is dependent on being financially, environmentally and socially responsible.
Our key values of openness, accountability and respect underpin our work to drive change for a healthier world. To help us live these values, 10 Essentials guide the decisions and actions of every Novo Nordisk colleague.
Novo Nordisk Pharmatech annual report 2023

Annual report

Our company

Contact us